Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | Emerging strategies to support patients with hemophilia A

Riitta Lassila • 10 Jun 2023
EHA 2023
Hemophilia Non-Malignant Antibodies Emicizumab

Riitta Lassila, MD, PhD, University of Helsinki, Helsinki, Finland, discusses recent developments in the treatment of hemophilia, mentioning the benefits of new drugs and strategies such as emicizumab. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Riitta Lassila

0:55
The importance of thrombosis and hemostasis in hematology & hot topics in hemophilia research
Riitta Lassila • 10 Jun 2023
1:43
Quality of life in patients with hemophilia: the impact of bleeds & the benefits of gene therapy
Riitta Lassila • 10 Jun 2023
1:06
Overview of the diagnostic work-up for hemophilia
Riitta Lassila • 10 Jun 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals